To examine the impact of additional confounder adjustment for the potential association between second line T2DM therapy and thyroid cancer: a nested case-control study (GLP1i and thyroid cancer)

First published 08/09/2023

Last updated 13/12/2023

EU PAS number:

EUPAS106600

Study

Finalised

Documents

Study protocol

Initial protocol

GLP1RA i and risk of thyroid cancer protocol

English (937.01 KB - PDF) View document

Study results

Study results Final

English (1.32 MB - PDF) View document

Study report

Other information

Publications

Study publications

Secondary tabs